|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
|
|
2
|
Provisor AJ, Ettinger LJ, Nachman JB,
Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES,
Kisker CT and Miser JS: Treatment of nonmetastatic osteosarcoma of
the extremity with preoperative and postoperative chemotherapy: A
report from the children's cancer group. J Clin Oncol. 15:76–84.
1997.PubMed/NCBI
|
|
3
|
Bacci G, Ferrari S, Bertoni F, Ruggieri P,
Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M and
Campanacci M: Long-term outcome for patients with nonmetastatic
osteosarcoma of the extremity treated at the istituto ortopedico
rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2
protocol: An updated report. J Clin Oncol. 18:4016–4027.
2000.PubMed/NCBI
|
|
4
|
Rytting M, Pearson P, Raymond AK, Ayala A,
Murray J, Yasko AW, Johnson M and Jaffe N: Osteosarcoma in
preadolescent patients. Clin Orthop Relat Res. 39–50. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hosking BM, Muscat GE, Koopman PA, Dowhan
DH and Dunn TL: Trans-activation and DNA-binding properties of the
transcription factor, Sox-18. Nucleic Acids Res. 23:2626–2628.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hosking BM, Wyeth JR, Pennisi DJ, Wang SC,
Koopman P and Muscat GE: Cloning and functional analysis of the
Sry-related HMG box gene, Sox18. Gene. 262:239–247. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Darby IA, Bisucci T, Raghoenath S, Olsson
J, Muscat GE and Koopman P: Sox18 is transiently expressed during
angiogenesis in granulation tissue of skin wounds with an identical
expression pattern to Flk-1 mRNA. Lab Invest. 81:937–943. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Young N, Hahn CN, Poh A, Dong C, Wilhelm
D, Olsson J, Muscat GE, Parsons P, Gamble JR and Koopman P: Effect
of disrupted SOX18 transcription factor function on tumor growth,
vascularization and endothelial development. J Natl Cancer Inst.
98:1060–1067. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eom BW, Jo MJ, Kook MC, Ryu KW, Choi IJ,
Nam BH, Kim YW and Lee JH: The lymphangiogenic factor SOX 18: A key
indicator to stage gastric tumor progression. Int J Cancer.
131:41–48. 2012. View Article : Google Scholar
|
|
11
|
Jethon A, P ula B, Olbromsk i M, Wer ynska
B, Muszczynska-Bernhard B, Witkiewicz W, Dziegiel P and
Podhorska-Okolow M: Prognostic significance of SOX18 expression in
non-small cell lung cancer. Int J Oncol. 46:123–132. 2015.
|
|
12
|
Pula B, Kobierzycki C, Solinski D,
Olbromski M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Zabel M and
Dziegiel P: SOX18 expression predicts response to platinum-based
chemotherapy in ovarian cancer. Anticancer Res. 34:4029–4037.
2014.PubMed/NCBI
|
|
13
|
Pula B, Olbromski M, Wojnar A,
Gomulkiewicz A, Witkiewicz W, Ugorski M, Dziegiel P and
Podhorska-Okolow M: Impact of SOX18 expression in cancer cells and
vessels on the outcome of invasive ductal breast carcinoma. Cell
Oncol (Dordr). 36:469–483. 2013. View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Henry MK, Lynch JT, Eapen AK and Quelle
FW: DNA damage-induced cell-cycle arrest of hematopoietic cells is
overridden by activation of the PI-3 kinase/Akt signaling pathway.
Blood. 98:834–841. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Silletti S, Paku S and Raz A: Autocrine
motility factor and the extracellular matrix. I. Coordinate
regulation of melanoma cell adhesion, spreading and migration
involves focal contact reorganization. Int J Cancer. 76:120–128.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mareel M, Oliveira MJ and Madani I: Cancer
invasion and metastasis: Interacting ecosystems. Virchows Arch.
454:599–622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wakefield LM and Roberts AB: TGF-beta
signaling: Positive and negative effects on tumorigenesis. Curr
Opin Genet Dev. 12:22–29. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kodama M, Kitadai Y, Sumida T, Ohnishi M,
Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W and Chayama K:
Expression of platelet-derived growth factor (PDGF)-B and
PDGF-receptor β is associated with lymphatic metastasis in human
gastric carcinoma. Cancer Sci. 101:1984–1989. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donnem T, Al-Saad S, Al-Shibli K, Busund
LT and Bremnes RM: Co-expression of PDGF-B and VEGFR-3 strongly
correlates with lymph node metastasis and poor survival in
non-small-cell lung cancer. Ann Oncol. 21:223–231. 2010. View Article : Google Scholar
|
|
21
|
Jechlinger M, Sommer A, Moriggl R, Seither
P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H and
Grünert S: Autocrine PDGFR signaling promotes mammary cancer
metastasis. J Clin Invest. 116:1561–1570. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Struckhoff AP, Rana MK and Worthylake RA:
RhoA can lead the way in tumor cell invasion and metastasis. Front
Biosci (Landmark Ed). 16:1915–1926. 2011. View Article : Google Scholar
|
|
23
|
Yan G, Zou R, Chen Z, Fan B, Wang Z, Wang
Y, Yin X, Zhang D, Tong L, Yang F, et al: Silencing RhoA inhibits
migration and invasion through Wnt/β-catenin pathway and growth
through cell cycle regulation in human tongue cancer. Acta Biochim
Biophys Sin (Shanghai). 46:682–690. 2014. View Article : Google Scholar
|
|
24
|
Yoshioka K, Nakamori S and Itoh K:
Overexpression of small GTP-binding protein RhoA promotes invasion
of tumor cells. Cancer Res. 59:2004–2010. 1999.PubMed/NCBI
|
|
25
|
Garcia-Ramírez M, Martinez-González J,
Juan-Babot JO, Rodríguez C and Badimon L: Transcription factor
SOX18 is expressed in human coronary atherosclerotic lesions and
regulates DNA synthesis and vascular cell growth. Arterioscler
Thromb Vasc Biol. 25:2398–2403. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Duong T, Proulx ST, Luciani P, Leroux JC,
Detmar M, Koopman P and Francois M: Genetic ablation of SOX18
function suppresses tumor lymphangiogenesis and metastasis of
melanoma in mice. Cancer Res. 72:3105–3114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ostman A: PDGF receptors-mediators of
autocrine tumor growth and regulators of tumor vasculature and
stroma. Cytokine Growth Factor Rev. 15:275–286. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Uehara H, Kim SJ, Karashima T, Shepherd
DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P and Fidler
IJ: Effects of blocking platelet-derived growth factor-receptor
signaling in a mouse model of experimental prostate cancer bone
metastases. J Natl Cancer Inst. 95:458–470. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sulzbacher I, Birner P, Trieb K, Träxler
M, Lang S and Chott A: Expression of platelet-derived growth
factor-AA is associated with tumor progression in osteosarcoma. Mod
Pathol. 16:66–71. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peterson JE, Zurakowski D, Italiano JE Jr,
Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL and Folkman
J: VEGF, PF4 and PDGF are elevated in platelets of colorectal
cancer patients. Angiogenesis. 15:265–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ariad S, Seymour L and Bezwoda WR:
Platelet-derived growth factor (PDGF) in plasma of breast cancer
patients: Correlation with stage and rate of progression. Breast
cancer Res Treat. 20:11–17. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abraham MT, Kuriakose MA, Sacks PG, Yee H,
Chiriboga L, Bearer EL and Delacure MD: Motility-related proteins
as markers for head and neck squamous cell cancer. Laryngoscope.
111:1285–1289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Horiuchi A, Imai T, Wang C, Ohira S, Feng
Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA
and RhoC, is associated with tumor progression in ovarian
carcinoma. Lab Invest. 83:861–870. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kamai T, Arai K, Tsujii T, Honda M and
Yoshida K: Overexpression of RhoA mRNA is associated with advanced
stage in testicular germ cell tumour. BJU International.
87:227–231. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kamai T, Tsujii T, Arai K, Takagi K, Asami
H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway
with invasion and metastasis of bladder cancer. Clin Cancer Res.
9:2632–2641. 2003.PubMed/NCBI
|
|
36
|
Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y,
Yao X, Zheng Y and Fan D: Reversal of the malignant phenotype of
gastric cancer cells by inhibition of RhoA expression and activity.
Clin Cancer Res. 10:6239–6247. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pillé JY, Denoyelle C, Varet J, Bertrand
JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, et
al: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and
invasiveness of MDA-MB-231 breast cancer cells in vitro and in
vivo. Mol Ther. 11:267–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
